V
26.95
2.09 (8.41%)
Penutupan Terdahulu | 24.86 |
Buka | 25.30 |
Jumlah Dagangan | 4,356,088 |
Purata Dagangan (3B) | 3,808,385 |
Modal Pasaran | 3,026,754,560 |
Harga / Buku (P/B) | 4.07 |
Julat 52 Minggu | |
Tarikh Pendapatan | 22 Jul 2025 - 28 Jul 2025 |
EPS Cair (TTM) | -1.16 |
Jumlah Hutang/Ekuiti (D/E MRQ) | 0.12% |
Nisbah Semasa (MRQ) | 44.25 |
Aliran Tunai Operasi (OCF TTM) | -133.99 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -98.38 M |
Pulangan Atas Aset (ROA TTM) | -11.74% |
Pulangan Atas Ekuiti (ROE TTM) | -14.40% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Menurun |
Biotechnology (Global) | Bercampur | Menurun | |
Stok | Viking Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
2.0
Konsensus Penganalisis | 5.0 |
Aktiviti Orang Dalam | -1.5 |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | 2.0 |
Purata | 2.00 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 2.12% |
% Dimiliki oleh Institusi | 70.04% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 104.00 (Cantor Fitzgerald, 285.90%) | Beli |
Median | 102.00 (278.48%) | |
Rendah | 75.00 (Truist Securities, 178.29%) | Beli |
Purata | 95.75 (255.29%) | |
Jumlah | 4 Beli | |
Harga Purata @ Panggilan | 26.16 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 25 Jun 2025 | 102.00 (278.48%) | Beli | 27.09 |
24 Apr 2025 | 102.00 (278.48%) | Beli | 25.66 | |
Cantor Fitzgerald | 28 Apr 2025 | 104.00 (285.90%) | Beli | 25.94 |
Truist Securities | 28 Apr 2025 | 75.00 (178.29%) | Beli | 25.94 |
Morgan Stanley | 24 Apr 2025 | 102.00 (278.48%) | Beli | 25.66 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
16 Jul 2025 | Pengumuman | Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 |
25 Jun 2025 | Pengumuman | Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 |
28 May 2025 | Pengumuman | Viking Therapeutics to Participate at Upcoming Investor Conferences |
23 Apr 2025 | Pengumuman | Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |